Targeted therapies for rare lung diseases

About
Us

Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, now in a Phase 2b study, is an inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.

Therapeutic
Focus

Avalyn is developing inhaled formulations of approved medications to treat rare respiratory diseases. Our initial focus is on the treatment of Interstitial Lung Diseases, including Pulmonary Fibrosis, and rare diseases that have dramatic impacts on patient quality of life.

News

October 8, 2024

Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree
Read more »

September 30, 2024

Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis
Read more »

September 8, 2024

Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024
Read more »

September 3, 2024

Avalyn Announces Initiation of its Global Phase 2b MIST Study of AP01 Inhaled Pirfenidone for Progressive Pulmonary Fibrosis
Read more »